The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

Jung, Hyejung, Bobba, Raja, Su, Jiandong, Shariati‐Sarabi, Zhaleh, Gladman, Dafna D., Urowitz, Murray, Lou, Wendy, Fortin, Paul R.·2010·Arthritis & Rheumatism
DOI 10.1002/art.27289

Cited by (291)

Items 101–200 of 291

  1. Cardiovascular Disease in Latin American Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study and a Systematic Review
    Jenny Amaya‐Amaya, Juan Camilo Sarmiento-Monroy, Julian Caro‐Moreno, Nicolás Molano‐González, Rubén D. Mantilla, Adriana Rojas‐Villarraga, Juan‐Manuel Anaya · 2013 · Autoimmune Diseases
  2. Treatment of antiphospholipid syndrome beyond anticoagulation
    Chrisanna Dobrowolski, Doruk Erkan · 2018 · Clinical Immunology
  3. How can we define low disease activity in systemic lupus erythematosus?
    Konstantinos Tselios, Dafna D. Gladman, Murray B. Urowitz · 2018 · Seminars in Arthritis and Rheumatism
  4. Pathogenesis and Treatment of Atherosclerosis in Lupus
    Maureen A. McMahon, Brian J. Skaggs · 2014 · Rheumatic Disease Clinics of North America
  5. Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus
    Qian Wang, Ziqian Wang, Shangzhu Zhang, Yang Wu, Li Zhang, Jiuliang Zhao, Qian Wang, Xinping Tian, Mengtao Li, Xiaofeng Zeng · 2022 · Journal of Clinical Medicine
  6. Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study
    Élisabeth Pasquier, Luc de Saint Martin, Gisèle Marhic, Céline Chauleur, Caroline Bohec, Florence Bretelle, V. Lejeune, Jacob Hannigsberg, Geneviève Plu‐Bureau, Virginie Cogulet et al. · 2019 · BMJ Open
  7. Cardiovascular disease in systemic lupus erythematosus
    Maureen A. McMahon, Richard Seto, Brian J. Skaggs · 2021 · Rheumatology and Immunology Research
  8. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial
    Otto Hartman, Petri T. Kovanen, Jukka Y. A. Lehtonen, Kari K. Eklund, Juha P. Sinisalo · 2016 · European Heart Journal - Cardiovascular Pharmacotherapy
  9. What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?
    Tzu‐Fei Wang, Wendy Lim · 2016 · Hematology
  10. Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
    Rania M. Sarhan, Hadeer S. Harb, Ahmed Essam Abou Warda, Mounir Mohamed Salem-Bekhit, Faiyaz Shakeel, Sami Ali Alzahrani, Yasmin M. Madney, Marian S. Boshra · 2021 · Journal of Infection and Public Health
  11. Neutrophil Extracellular Traps and Respiratory Disease
    Paul T. King, Lovisa F. Dousha · 2024 · Journal of Clinical Medicine
  12. Diagnosis and treatment of antiphospholipid syndrome in childhood: A review
    Dax G. Rumsey, Barry Lee Myones, Patti Massicotte · 2017 · Blood Cells Molecules and Diseases
  13. Systemic Lupus Erythematosus
    Chaim Putterman, Roberto Caricchio, Anne Davidson, Harris Perlman · 2012 · Clinical and Developmental Immunology
  14. Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation
    Lauren Bourke, James McCormick, Valerie Taylor, Charis Pericleous, Benoı̂t Blanchet, Nathalie Costedoat-Chalumeau, Daniel J. Stuckey, Mark F. Lythgoe, Anastasis Stephanou, Yiannis Ioannou · 2015 · PLoS ONE
  15. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers
    Seyed Mostafa Monzavi, Aida Alirezaei, Zhaleh Shariati‐Sarabi, Jalil Tavakol Afshari, Mahmoud Mahmoudi, Banafshe Dormanesh, Faeze Jahandoost, Alireza Khoshdel, Ali Etemad Rezaie · 2018 · Inflammopharmacology
  16. Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?
    Konstantinos Tselios, Dafna D. Gladman, Paula Harvey, Shadi Akhtari, Jiandong Su, Murray B. Urowitz · 2018 · The Journal of Rheumatology
  17. Systemic lupus erythematosus is a risk factor for cardiovascular disease: a nationwide, population-based study in Korea
    Sang-Yeob Lim, Eun Hui Bae, Kyung Do Han, JH Jung, Hong Sang Choi, H. Y. Kim, Chang Sub Kim, S. K. Ma, Soo Wan Kim · 2018 · Lupus
  18. The national incidence and clinical picture of SLE in children in Australia – a report from the Australian Paediatric Surveillance Unit
    Fiona Mackie, Gad Kainer, N. Adib, C Boros, Elizabeth Jane Elliott, Rose Fahy, Jane E. Munro, Kevin J. Murray, Andrew R. Rosenberg, Brynn Kevin Wainstein et al. · 2014 · Lupus
  19. Antimalarials in Dermatology: Mechanism of Action, Indications, and Side Effects
    Clara Rodríguez-Caruncho, Isabel Bielsa · 2014 · Actas Dermo-Sifiliográficas
  20. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    G. W. Naerr, P. Rein, C. Saely, H. Drexel · 2016 · Vascular pharmacology
  21. Prevention and management of co-morbidities in SLE
    Tanmayee Bichile, Michelle Petri · 2014 · La Presse Médicale
  22. Factors associated with health-related quality of life in Peruvian patients with systemic lupus erythematosus
    Claudia Elera‐Fitzcarrald, Magaly Alva, Rocio Violeta Gamboa-Cardenas, Claudia S Mora-Trujillo, Francisco Zevallos, Augusto García-Poma, Mariela Medina, Zoila Rodríguez‐Bellido, Risto Alfredo Perich-Campos, Cesar Augusto Pastor-Asurza et al. · 2018 · Lupus
  23. The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy
    Brenna D. Appleton, Amy Stasny Major · 2020 · Current Opinion in Rheumatology
  24. Cytokine targets in lupus nephritis: Current and future prospects
    Christina Adamichou, Spiros Georgakis, George K Bertsias · 2018 · Clinical Immunology
  25. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort
    Murray B. Urowitz, Dafna D. Gladman, Vernon Todd Farewell, Jiandong Su, Juanita Romero‐Díaz, Sang‐Cheol Bae, Paul R. Fortin, Jorge Sánchez‐Guerrero, Ann Elaine Clarke, Sasha Bernatsky et al. · 2020 · Arthritis & Rheumatology
  26. Management of cardiovascular disease in patients with systemic lupus erythematosus
    Paramarajan Piranavan, András Perl · 2020 · Expert Opinion on Pharmacotherapy
  27. Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management
    Silvia Rosina, Cecilia Beatrice Chighizola, Angelo Ravelli, Rolando Cimaz · 2021 · Current Rheumatology Reports
  28. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study
    Yao‐Min Hung, Yu‐Hsun Wang, Lichi Lin, Paul Yung Pou Wang, Jeng‐Yuan Chiou, James Cheng‐Chung Wei · 2018 · International Journal of Clinical Practice
  29. The Effect of Mycophenolate Mofetil on Disease Development in the gld.apoE−/− Mouse Model of Accelerated Atherosclerosis and Systemic Lupus Erythematosus
    Christophe Richez, Rocco J. Richards, P. Duffau, Zachary N. Weitzner, Chris Andry, Ian R. Rifkin, Tamar R. Aprahamian · 2013 · PLoS ONE
  30. Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review
    Francesco Benvenuti, Mariele Gatto, Maddalena Larosa, Luca Iaccarino, Leonardo Punzi, Andrea Doria · 2015 · Expert Opinion on Drug Safety
  31. Pregnancy outcomes in systemic lupus erythematosus (SLE) women
    Aida Hani Mohd Kalok, Rizna Abdul Cader, Ima Indirayani, Abdul Karim, Shamsul Azhar Shah, Nor Azlin Mohamed Ismail, Mohd Hashim Omar, Mohamad Nasir Shafiee · 2019 · Hormone Molecular Biology and Clinical Investigation
  32. Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician
    Teresa Semalulu, Achieng Tago, Kevin Zhao, Konstantinos Tselios · 2023 · ImmunoTargets and Therapy
  33. Antiphospholipid syndrome: an update for clinicians and scientists
    Vreede, Andrew P., Bockenstedt, Paula L., Knight, Jason S. · 2017 · Current Opinion in Rheumatology
  34. Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial
    Fatma Sayed Gheet, Heba Dawoud, Waleed Ahmed El-Shehaby, Shaymaa Mohamed Elrifaey, Hend Hassan Abdelnabi · 2023 · European Journal of Pediatrics
  35. Cardiovascular Risk in Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Disorders: a Suggested Model of Preventive Strategy
    Elena Bartoloni, Alessia Alunno, Onelia Bistoni, Roberto Gerli · 2011 · Clinical Reviews in Allergy & Immunology
  36. Guía de práctica clínica para el lupus eritematoso sistémico: recomendaciones para el abordaje clínico general
    María M. Trujillo‐Martín, Íñigo Rúa-Figueroa Fernández de Larrinoa, Guillermo Ruiz‐Irastorza, José María Pego‐Reigosa, José Mario Sabio, Pedro Guillermo Serrano-Aguilar · 2016 · Medicina Clínica
  37. Management of cardiovascular risk in systemic lupus erythematosus: a systematic review
    C Andrades, C. Fuego, Sara Manrique Arija, Antonio Fernández‐Nebro · 2017 · Lupus
  38. Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus
    Alisha Gupta, Kelly J. Shields, Susan Manzi, Mary Chester Wasko, Tarun S. Sharma · 2020 · Arthritis Care & Research
  39. Hydroxychloroquine: A double‑edged sword (Review)
    Rongxiu Huo, Chengcheng Wei, Yanting Yang, Jinying Lin, Xinxiang Huang · 2025 · Molecular Medicine Reports
  40. Hydroxychloroquine, a promising choice for coronary artery disease?
    Lizhe Sun, Mengping Liu, Ruifeng Li, Qiang Zhao, Junhui Liu, Yanjie Yang, Lisha Zhang, Xiaofang Bai, Yuanyuan Wei, Qiang-Qiang Ma et al. · 2016 · Medical Hypotheses
  41. Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis
    Emily Keyes, Madison Grinnell, Douglas S. Jacoby, Thomas Vazquez, DeAnna Diaz, Victoria P. Werth, Kevin Jon Williams · 2021 · International Journal of Women’s Dermatology
  42. Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus
    Paola C. Roldan, Ernest R. Greene, Clifford Qualls, Wilmer L. Sibbitt, Carlos A. Roldan · 2019 · Rheumatology International
  43. Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE
    Maureen A. McMahon, Brian J. Skaggs, Jennifer M. Grossman, Weng Kee Wong, Lori Sahakian, Weiling Chen, Bevra Hahn · 2019 · Lupus Science & Medicine
  44. Primary prevention in antiphospholipid antibody carriers
    MT Bertero · 2012 · Lupus
  45. Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
    Elena Bartoloni, Fabio Cacciapaglia, Gian Luca Erre, Elisa Gremese, Andreina Manfredi, Matteo Piga, Garifallia Sakellariou, Francesca Romana Spinelli, Ombretta Viapiana, Fabiola Atzeni · 2025 · Autoimmunity Reviews
  46. Do all lupus patients need statins?
    Martin Soubrier, Sylvain Mathieu, M. Hermet, Claudie Makarawiez, Éric Bruckert · 2012 · Joint Bone Spine
  47. Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population‐based retrospective cohort study
    Hong‐Wei Tam, Chyong‐Mei Chen, Pui‐Ying Leong, Chao-Hsi Chen, Yuanchao Li, Yu‐Hsun Wang, Lichi Lin, Jeng‐Yuan Chiou, James Cheng‐Chung Wei · 2018 · International Journal of Rheumatic Diseases
  48. Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?
    Xiping Zhan, Sharon Dowell, Ying Shen, Dexter L. Lee · 2020 · Heliyon
  49. Rapid sensitive bioscreening of remdesivir in COVID-19 medication: Selective drug determination in the presence of six co-administered therapeutics
    Mona M. Abdel Moneim, Miranda F. Kamal, Mohamed M. A. Hamdy · 2021 · Reviews in Analytical Chemistry
  50. What is known about pediatric antiphospholipid syndrome?
    Pier Luigi Meroni, Lorenza Maria Argolini, Irene Pontikaki · 2016 · Expert Review of Hematology
  51. Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus
    Wen-Jun Yuan, Fengjun Guan · 2022 · Autoimmune Diseases
  52. Athérosclérose au cours du lupus érythémateux systémique
    Zoubida Mezalek Tazi, H. Harmouche, Wafaa Ammouri, M. Maamar, Mohamed Adnaoui, P. Cacoub · 2014 · La Presse Médicale
  53. Molecular mechanisms underlying thrombosis in systemic lupus erythematosus – A Systematic review
    Mads Lamm Larsen, Laura Nørgaard, Petrus Linge, Julie Brogaard Larsen, Henrik Zachar Langkilde, Ellen‐Margrethe Hauge, Steffen Thiel, Anne Voss, Anders A Bengtsson, Anne Troldborg · 2025 · Seminars in Arthritis and Rheumatism
  54. Reviewing the Recommendations for Lupus in Children
    Zehra Serap Arıcı, Ezgi Deniz Batu, Seza Özen · 2015 · Current Rheumatology Reports
  55. Hydroxychloroquine decreases human MSC ‐derived osteoblast differentiation and mineralization in vitro
    Tim Both, Jeroen van de Peppel, M. Carola Zillikens, Marijke Koedam, Johannes P.T.M. van Leeuwen, P. Martin van Hagen, Paul L. A. van Daele, Bram C. J. van der Eerden · 2017 · Journal of Cellular and Molecular Medicine
  56. Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus
    Suzan Dahdal, Vasilios Devetzis, Georgios K. Chalikias, Dimitrios N. Tziakas, Carlo Chizzolini, Camillo Ribi, Marten Trendelenburg, Ute Eisenberger, Thomas Hauser, Andreas Pasch et al. · 2018 · PLoS ONE
  57. New therapeutic avenues in SLE
    Jyoti Bakshi, Mediola Ismajli, Anisur Rahman · 2015 · Best Practice & Research Clinical Rheumatology
  58. Cardiovascular disease risk in systemic lupus erythematous: Certainties and controversies
    Fabiola Atzeni, Ignasi Rodríguez‐Pintó, Ricard Cervera · 2024 · Autoimmunity Reviews
  59. Hydroxychloroquine : une nouvelle approche thérapeutique des manifestations thrombotiques du syndrome des antiphospholipides
    Jean Szymezak, Annick Ankri, Anne‐Marie Fischer, Luc Darnige · 2010 · La Revue de Médecine Interne
  60. Use of Hydroxychloroquine in Japan
    Mitsumasa Kishimoto, Gautam Anil Deshpande, Naoto Yokogawa, Jill P. Buyon, Masato Okada · 2012 · The Journal of Rheumatology
  61. Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management
    María M. Trujillo‐Martín, Íñigo Rúa-Figueroa Fernández de Larrinoa, Guillermo Ruiz‐Irastorza, José María Pego‐Reigosa, José Mario Sabio, Pedro Guillermo Serrano-Aguilar · 2016 · Medicina Clínica (English Edition)
  62. Deciphering the clinical significance of longitudinal antiphospholipid antibody titers
    Cecilia Beatrice Chighizola, Rohan Willis, Gabriella Maioli, Savino Sciascia, Laura Andréoli, Olga Amengual, Massimo Radin, Maria Gerosa, Tatsuya Atsumi, Guilherme Ramires de Jesús et al. · 2024 · Autoimmunity Reviews
  63. Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century—an observational study from the Lupus-Cruces cohort
    Amaia Ugarte, Alazne Garcia de Bustos, Ioana Ruiz‐Arruza, Adriana Soto-Peleteiro, Daniel Martín‐Iglesias, Cristina González-Echávarri, Guillermo Ruiz‐Irastorza · 2021 · Rheumatology
  64. Farrerol ameliorate adjuvant-induced ankle injury via alteration of PPAR-γ signal pathway.
    Zhao Tian, Hong-Xing Zhang, Chi Shang · 2021 · Journal of food biochemistry
  65. Aortic Atherosclerosis in Systemic Lupus Erythematosus
    Paola C. Roldan · 2013 · Rheumatology Current Research
  66. The neurology of lupus
    John G. Hanly, Murat İnanç · 2021 · Journal of the Neurological Sciences
  67. Clinical profiles and risk assessment in patients with antiphospholipid antibodies
    Masaru Kato, Ryo Hisada, Tatsuya Atsumi · 2018 · Expert Review of Clinical Immunology
  68. B cells and atherosclerosis in systemic lupus erythematosus
    Vasiliki Koulouri, Michael Koutsilieris, Clio P. Mavragani · 2019 · Expert Review of Clinical Immunology
  69. Renin-Angiotensin System-Modifying Antihypertensive Drugs Can Reduce the Risk of Cardiovascular Complications in Lupus: A Retrospective Cohort Study
    Chelsie Hurst, Maira Soto, Ernest R. Vina, Kathleen E. Rodgers · 2022 · The American Journal of Medicine
  70. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study
    Jie Chen, Shuhui Sun, Qingran Yan, Chunde Bao, Qiong Fu · 2016 · Clinical Rheumatology
  71. Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
    Gerwyn Morris, Eugene Athan, Ken R. Walder, Chiara C. Bortolasci, Adrienne E O'Neil, Wolfgang Marx, Michael Berk, Andre Ferrer Carvalho, Michael H. J. Maes, Basant K. Puri · 2020 · Life Sciences
  72. Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus
    Liu Peng-Cheng, Lv Meng-Na, Jianbin Li, Yu Shu-Jiao, Rui Wu · 2024 · Heliyon
  73. Atherosclerosis in Systemic Lupus Erythematosus – Epidemiology, Risk Factors, Subclinical Assessment and Future Study
    Barry J. Sheane · 2013 · Rheumatology Current Research
  74. Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness ( RISE ) Registry Data Review
    Christie Michels Bartels, April M Jorge, Candace H. Feldman, JoAnn Zell, Bonnie Lee Bermas, Claire E.H. Barber, Alí Duarte‐García, Shivani Garg, Leah A. Haseley, Shraddha Jatwani et al. · 2023 · Arthritis Care & Research
  75. Hydroxychloroquine as an important immunomodulator: a novel insight into an old drug
    Katarzyna Krystyna Pawlak-Buś, Piotr Leszczyński · 2024 · Polskie Archiwum Medycyny Wewnętrznej
  76. Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study
    Anna R. Broder, Wenzhu Bi Mowrey, Mimi Kim, Irina Murakhovskaya, Henny Heisler Billett, Joel Neugarten, Karen H. Costenbader, Chaim Putterman · 2015 · Rheumatology
  77. Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network
    Mar Fernández‐Garcés, Gonzalo Haro, María Luisa Micó · 2019 · Medicine
  78. Hydroxychloroquine in systemic lupus erythematosus, anti-SSA/SSB, and antiphospholipid antibody-positive pregnancies
    Zeinab Saleh, Emily C. Somers, Vivian Romero, Wendy Marder · 2025 · American Journal of Obstetrics and Gynecology
  79. Recent progress in conventional and biologic therapy for systemic lupus erythematosus
    David Wofsy · 2012 · Annals of the Rheumatic Diseases
  80. The Risky Business of Studying Prognosis
    Lily Siok Hoon Lim, Brian Michael Feldman · 2012 · The Journal of Rheumatology
  81. Antimalarial medications
    Juan Antonio Aviña-Zubieta, Narsis Daftarian, John M. Esdaile · 2024 · Elsevier eBooks
  82. Diagnosis and Management of Pediatric Neuropsychiatric Systemic Lupus Erythematosus: An Update
    Dilara Ünal, Veysel Çam, Hülya Ercan Emreol, Seza Özen · 2024 · Pediatric Drugs
  83. Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice
    Michelle Petri · 2011 · International Journal of Rheumatic Diseases
  84. Anti-malarials: Are There Benefits Beyond Mild Disease?
    Tarun S. Sharma, Erika Joyce, Mary Chester Wasko · 2016 · Current Treatment Options in Rheumatology
  85. Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
    Christian Albert Devaux, Laurence Camoin‐Jau, Jean‐Louis Mège, Didier Raoult · 2021 · Journal of Microbiology Immunology and Infection
  86. Le risque cardiovasculaire au cours du lupus systémique
    Laurent Arnaud, Alexis Mathian, Éric Bruckert, Zahir Amoura · 2014 · La Revue de Médecine Interne
  87. Acute Coronary Syndromes in Antiphospholipid Syndrome-above Suspicion: A Systematic Review
    Vasileios Nevras, Nikias Milaras, Christos Katsioulis, Zoi Sotiriou, Sotirios Tsalamandris, Georgia Gkounti, Skevos K. Sideris · 2022 · Current Problems in Cardiology
  88. Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs)
    Iordanis S. Mourouzis, Antonis S. Manolis, Constantinos I. Pantos · 2019 · Current Vascular Pharmacology
  89. Aortic adventitial thickness as a marker of aortic atherosclerosis, vascular stiffness, and vessel remodeling in systemic lupus erythematosus
    Luis Pablo Roldan, Paola C. Roldan, Wilmer L. Sibbitt, Clifford Qualls, Michelle D. Ratliff, Carlos A. Roldan · 2020 · Clinical Rheumatology
  90. Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers
    Ilenia Lorenza Calcaterra, Pasquale Ambrosino, Nicoletta Vitelli, Roberta Lupoli, Roberta Clara Orsini, Martina Chiurazzi, Mauro Maniscalco, Matteo Nicola Dario Di Minno · 2021 · Biomedicines
  91. The Role of Hydroxychloroquine in the Management of Rheumatic Disorders: A Comprehensive Review
    İlker Ateş, Hilal Sahin, Lalu Muhammad Irham, Serkan Yılmaz, Halit Sinan Suzen · 2025 · Basic & Clinical Pharmacology & Toxicology
  92. An observational study to identify causative factors for not using hydroxychloroquine in systemic lupus erythematosus
    Atsushi Manabe, Ryuichi Minoda Sada, Hirofumi Miyake, Hiroyuki Akebo, Yukio Tsugihashi, Kazuhiro Hatta · 2024 · Scientific Reports
  93. Neurological Manifestations of Systemic Lupus Erythematosus: A Comprehensive Review
    Maleesha Jayasinghe, Fatemeh Rashidi, Ahmed Farid Gadelmawla, Jamir Pitton Rissardo, Masoumeh Rashidi, Christopher C Elendu, Ana Letícia Fornari Caprara, Ibrahim Khalil, Khalil Iyad, Mona M. Atef et al. · 2025 · Cureus
  94. Pathological manifestation of autoimmune myocarditis is detected prior to glomerulonephritis in a murine model of lupus nephritis
    Nicholas A. Young, Kyle Jablonski, Emmy Schwarz, Ifeoma Okafor, Jeffrey M. Hampton, Giancarlo R. Valiente, Caitlin Henry, Peter Harb, Jessica Barger, Anna Bratasz et al. · 2020 · Lupus
  95. Drug monitoring in systemic lupus erythematosus
    Michelle Petri · 2022 · Current Opinion in Pharmacology
  96. Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study
    Sigrid Reppe Moe, Hilde Haukeland, Cathrine Brunborg, Antonela Botea, Nenad Damjanic, Gro Årthun Wivestad, Heidi Kverneggen Øvreås, Thea Bjerkestrand Bøe, Anniken Orre, Torhild Garen et al. · 2025 · RMD Open
  97. Top 10 Clinical Research Developments in Antiphospholipid Syndrome
    Medha Barbhaiya, Doruk Erkan · 2013 · Current Rheumatology Reports
  98. Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea
    Sooyoung Shin · 2017 · Patient Preference and Adherence
  99. Immunotherapeutic strategies in antiphospholipid syndrome
    Alberta Yik-Bun Hoi, Laura Ross, J. Day, Russell R. C. Buchanan · 2016 · Internal Medicine Journal
  100. Hydroxychloroquine Use Is Not Associated With QTc Length in a Large Cohort of SLE and RA Patients
    Elizabeth Park, Jon T. Giles, Thania Perez-Recio, Paloma Piña, C. Depender, Yevgeniya Gartshteyn, Anca Askanase, Joan M. Bathon, Laura B. Geraldino-Pardilla · 2021 · Research Square